96 related articles for article (PubMed ID: 3717079)
1. Phase I study of thymidine (dThd) and cisplatin (DDP) given in combination.
Chiuten DF; Valdivieso M; Benvenuto JA; Drewinko B; Bedikian A; Bodey GP
Am J Clin Oncol; 1986 Apr; 9(2):129-31. PubMed ID: 3717079
[TBL] [Abstract][Full Text] [Related]
2. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
Schilsky RL; O'Laughlin K; Ratain MJ
Cancer Res; 1986 Aug; 46(8):4184-8. PubMed ID: 3731086
[TBL] [Abstract][Full Text] [Related]
7. Clinical phase I-II and pharmacokinetic study of high-dose thymidine given by continuous intravenous infusion.
Chiuten DF; Wiernik PH; Zaharko DS; Edwards L
Cancer Res; 1980 Mar; 40(3):818-22. PubMed ID: 7471098
[TBL] [Abstract][Full Text] [Related]
8. [Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Zhang P; Feng FY; Wu LY; Hu Y; Liu JW; Gao YJ; Guan XQ; Nan KJ; Suo AL; Wang XW; Zhang MH; Zhang WD; Li CW; Zhang Y; Zhao JB
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):230-4. PubMed ID: 16875614
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the combination of monthly carboplatin and weekly cisplatin.
Sessa C; Goldhirsch A; Martinelli G; Alerci M; Imburgia L; Cavalli F
Ann Oncol; 1991 Feb; 2(2):123-9. PubMed ID: 2054313
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer.
Giaccone G; Donadio M; Ferrati P; Calciati A
Tumori; 1988 Apr; 74(2):191-3. PubMed ID: 3368973
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer.
Trudeau M; Zukiwski A; Langleben A; Boos G; Batist G
Cancer Chemother Pharmacol; 1995; 35(6):496-500. PubMed ID: 7882458
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Nardi M; De Marco S; Fabi A; Aloe A; Magnani E; Pacetti U; Carlini P; Ruggeri EM; Cognetti F
Cancer Chemother Pharmacol; 2001 Sep; 48(3):255-8. PubMed ID: 11592349
[TBL] [Abstract][Full Text] [Related]
14. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
Trump DL; Grem JL; Tutsch KD; Willson JK; Simon KJ; Alberti D; Storer B; Tormey DC
J Clin Oncol; 1987 Aug; 5(8):1281-9. PubMed ID: 3040920
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Pronk LC; Schellens JH; Planting AS; van den Bent MJ; Hilkens PH; van der Burg ME; de Boer-Dennert M; Ma J; Blanc C; Harteveld M; Bruno R; Stoter G; Verweij J
J Clin Oncol; 1997 Mar; 15(3):1071-9. PubMed ID: 9060547
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract.
Khandekar JD; Elson PJ; DeWys WD; Slayton RE; Harris DT
J Clin Oncol; 1985 Apr; 3(4):539-45. PubMed ID: 3884746
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
20. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
